Incidence and risk factors of bisphosphonate-associated osteonecrosis of the jaws
Background Intravenous bisphosphonate therapy has been used for treatment of benign and malignant bone diseases and has been linked to osteonecrosis of the jaws. Methods Records of 638 patients treated with intravenous bisphosphonates were reviewed. Drug used, number of infusions, dosing interval, d...
Gespeichert in:
| Veröffentlicht in: | Head & neck 2009-02, Vol.31 (2), p.202-206 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 206 |
|---|---|
| container_issue | 2 |
| container_start_page | 202 |
| container_title | Head & neck |
| container_volume | 31 |
| creator | Stumpe, Matthew R. Chandra, Rakesh K. Yunus, Furhan Samant, Sandeep |
| description | Background
Intravenous bisphosphonate therapy has been used for treatment of benign and malignant bone diseases and has been linked to osteonecrosis of the jaws.
Methods
Records of 638 patients treated with intravenous bisphosphonates were reviewed. Drug used, number of infusions, dosing interval, dosage, duration, and occasion of osteonecrosis, diagnosed by history and physical examination, were analyzed.
Results
The overall incidence of osteonecrosis was 0.94% (6/638). No significant relationship was observed between the incidence of osteonecrosis and demographic parameters, primary tumor, cumulative drug dose, or dosing interval. However, patients who developed osteonecrosis had a significantly greater mean number of infusions (p = .016) and significantly greater mean hours of infusion time (p = .0036).
Conclusions
The findings suggest positive correlation between the development of osteonecrosis and drug exposure as measured by number of infusions and total infusion hours. However, the relatively low incidence of osteonecrosis precluded definition of a direct dose–response relationship. © 2008 Wiley Periodicals, Inc. Head Neck, 2009 |
| doi_str_mv | 10.1002/hed.20941 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_902335794</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>902335794</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4491-f991300948ba934b2638e18719997000a3f6a648f36d74ae3aa95de2ef9781b53</originalsourceid><addsrcrecordid>eNp1kE1P3DAQhq2qFVDg0D9Q5VJVHAJ27MTxsd0Ci4T4ECCO1iQZaw3ZeOvJCvj39bLL3nqwPBo9M_PqYeyb4MeC8-Jkht1xwY0Sn9ie4EbnXCr9eVUrmUuu1S77SvTEOZeVKnbYrqjrUqpS7bHbi6H1HQ4tZjB0WfT0nDloxxApCy5rPC1mYfUGGDEHotD6VHVZoBHDgG0M5N_RcYbZE7zQAfvioCc83Pz77OHs9H4yzS-vzy8mvy7zVikjcmeMkDyFrhswUjVFJWsUtRbGGJ2SgnQVVKp2suq0ApQApuywQGd0LZpS7rOf672LGP4ukUY799Ri38OAYUnW8ELKUhuVyKM1uQpLEZ1dRD-H-GYFtyuBNgm07wIT-32zddnMU3dLbowl4McGAGqhdxGSQNpyheCiTljiTtbci-_x7f8X7fT0z8fpfD3hk9rX7QTEZ1tpqUv7eHVupzePv-8mk8IK-Q8By5U3</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>902335794</pqid></control><display><type>article</type><title>Incidence and risk factors of bisphosphonate-associated osteonecrosis of the jaws</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Stumpe, Matthew R. ; Chandra, Rakesh K. ; Yunus, Furhan ; Samant, Sandeep</creator><creatorcontrib>Stumpe, Matthew R. ; Chandra, Rakesh K. ; Yunus, Furhan ; Samant, Sandeep</creatorcontrib><description>Background
Intravenous bisphosphonate therapy has been used for treatment of benign and malignant bone diseases and has been linked to osteonecrosis of the jaws.
Methods
Records of 638 patients treated with intravenous bisphosphonates were reviewed. Drug used, number of infusions, dosing interval, dosage, duration, and occasion of osteonecrosis, diagnosed by history and physical examination, were analyzed.
Results
The overall incidence of osteonecrosis was 0.94% (6/638). No significant relationship was observed between the incidence of osteonecrosis and demographic parameters, primary tumor, cumulative drug dose, or dosing interval. However, patients who developed osteonecrosis had a significantly greater mean number of infusions (p = .016) and significantly greater mean hours of infusion time (p = .0036).
Conclusions
The findings suggest positive correlation between the development of osteonecrosis and drug exposure as measured by number of infusions and total infusion hours. However, the relatively low incidence of osteonecrosis precluded definition of a direct dose–response relationship. © 2008 Wiley Periodicals, Inc. Head Neck, 2009</description><identifier>ISSN: 1043-3074</identifier><identifier>EISSN: 1097-0347</identifier><identifier>DOI: 10.1002/hed.20941</identifier><identifier>PMID: 18853454</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Biological and medical sciences ; bisphosphonate ; Bone Density Conservation Agents - adverse effects ; Bones, joints and connective tissue. Antiinflammatory agents ; Cohort Studies ; Diphosphonates - adverse effects ; Diseases of the osteoarticular system ; Dose-Response Relationship, Drug ; Female ; Humans ; Incidence ; Infusions, Intravenous ; Male ; Mandible ; Maxilla ; Medical sciences ; Middle Aged ; osteonecrosis ; Osteonecrosis - chemically induced ; Osteonecrosis - epidemiology ; Otorhinolaryngology. Stomatology ; Pharmacology. Drug treatments ; Retrospective Studies ; Risk Factors ; Vascular bone diseases</subject><ispartof>Head & neck, 2009-02, Vol.31 (2), p.202-206</ispartof><rights>Copyright © 2008 Wiley Periodicals, Inc.</rights><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4491-f991300948ba934b2638e18719997000a3f6a648f36d74ae3aa95de2ef9781b53</citedby><cites>FETCH-LOGICAL-c4491-f991300948ba934b2638e18719997000a3f6a648f36d74ae3aa95de2ef9781b53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fhed.20941$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fhed.20941$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,782,786,1419,27931,27932,45581,45582</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21018543$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18853454$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stumpe, Matthew R.</creatorcontrib><creatorcontrib>Chandra, Rakesh K.</creatorcontrib><creatorcontrib>Yunus, Furhan</creatorcontrib><creatorcontrib>Samant, Sandeep</creatorcontrib><title>Incidence and risk factors of bisphosphonate-associated osteonecrosis of the jaws</title><title>Head & neck</title><addtitle>Head Neck</addtitle><description>Background
Intravenous bisphosphonate therapy has been used for treatment of benign and malignant bone diseases and has been linked to osteonecrosis of the jaws.
Methods
Records of 638 patients treated with intravenous bisphosphonates were reviewed. Drug used, number of infusions, dosing interval, dosage, duration, and occasion of osteonecrosis, diagnosed by history and physical examination, were analyzed.
Results
The overall incidence of osteonecrosis was 0.94% (6/638). No significant relationship was observed between the incidence of osteonecrosis and demographic parameters, primary tumor, cumulative drug dose, or dosing interval. However, patients who developed osteonecrosis had a significantly greater mean number of infusions (p = .016) and significantly greater mean hours of infusion time (p = .0036).
Conclusions
The findings suggest positive correlation between the development of osteonecrosis and drug exposure as measured by number of infusions and total infusion hours. However, the relatively low incidence of osteonecrosis precluded definition of a direct dose–response relationship. © 2008 Wiley Periodicals, Inc. Head Neck, 2009</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>bisphosphonate</subject><subject>Bone Density Conservation Agents - adverse effects</subject><subject>Bones, joints and connective tissue. Antiinflammatory agents</subject><subject>Cohort Studies</subject><subject>Diphosphonates - adverse effects</subject><subject>Diseases of the osteoarticular system</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>Humans</subject><subject>Incidence</subject><subject>Infusions, Intravenous</subject><subject>Male</subject><subject>Mandible</subject><subject>Maxilla</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>osteonecrosis</subject><subject>Osteonecrosis - chemically induced</subject><subject>Osteonecrosis - epidemiology</subject><subject>Otorhinolaryngology. Stomatology</subject><subject>Pharmacology. Drug treatments</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Vascular bone diseases</subject><issn>1043-3074</issn><issn>1097-0347</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kE1P3DAQhq2qFVDg0D9Q5VJVHAJ27MTxsd0Ci4T4ECCO1iQZaw3ZeOvJCvj39bLL3nqwPBo9M_PqYeyb4MeC8-Jkht1xwY0Sn9ie4EbnXCr9eVUrmUuu1S77SvTEOZeVKnbYrqjrUqpS7bHbi6H1HQ4tZjB0WfT0nDloxxApCy5rPC1mYfUGGDEHotD6VHVZoBHDgG0M5N_RcYbZE7zQAfvioCc83Pz77OHs9H4yzS-vzy8mvy7zVikjcmeMkDyFrhswUjVFJWsUtRbGGJ2SgnQVVKp2suq0ApQApuywQGd0LZpS7rOf672LGP4ukUY799Ri38OAYUnW8ELKUhuVyKM1uQpLEZ1dRD-H-GYFtyuBNgm07wIT-32zddnMU3dLbowl4McGAGqhdxGSQNpyheCiTljiTtbci-_x7f8X7fT0z8fpfD3hk9rX7QTEZ1tpqUv7eHVupzePv-8mk8IK-Q8By5U3</recordid><startdate>200902</startdate><enddate>200902</enddate><creator>Stumpe, Matthew R.</creator><creator>Chandra, Rakesh K.</creator><creator>Yunus, Furhan</creator><creator>Samant, Sandeep</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope></search><sort><creationdate>200902</creationdate><title>Incidence and risk factors of bisphosphonate-associated osteonecrosis of the jaws</title><author>Stumpe, Matthew R. ; Chandra, Rakesh K. ; Yunus, Furhan ; Samant, Sandeep</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4491-f991300948ba934b2638e18719997000a3f6a648f36d74ae3aa95de2ef9781b53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>bisphosphonate</topic><topic>Bone Density Conservation Agents - adverse effects</topic><topic>Bones, joints and connective tissue. Antiinflammatory agents</topic><topic>Cohort Studies</topic><topic>Diphosphonates - adverse effects</topic><topic>Diseases of the osteoarticular system</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>Humans</topic><topic>Incidence</topic><topic>Infusions, Intravenous</topic><topic>Male</topic><topic>Mandible</topic><topic>Maxilla</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>osteonecrosis</topic><topic>Osteonecrosis - chemically induced</topic><topic>Osteonecrosis - epidemiology</topic><topic>Otorhinolaryngology. Stomatology</topic><topic>Pharmacology. Drug treatments</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Vascular bone diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stumpe, Matthew R.</creatorcontrib><creatorcontrib>Chandra, Rakesh K.</creatorcontrib><creatorcontrib>Yunus, Furhan</creatorcontrib><creatorcontrib>Samant, Sandeep</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><jtitle>Head & neck</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stumpe, Matthew R.</au><au>Chandra, Rakesh K.</au><au>Yunus, Furhan</au><au>Samant, Sandeep</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Incidence and risk factors of bisphosphonate-associated osteonecrosis of the jaws</atitle><jtitle>Head & neck</jtitle><addtitle>Head Neck</addtitle><date>2009-02</date><risdate>2009</risdate><volume>31</volume><issue>2</issue><spage>202</spage><epage>206</epage><pages>202-206</pages><issn>1043-3074</issn><eissn>1097-0347</eissn><abstract>Background
Intravenous bisphosphonate therapy has been used for treatment of benign and malignant bone diseases and has been linked to osteonecrosis of the jaws.
Methods
Records of 638 patients treated with intravenous bisphosphonates were reviewed. Drug used, number of infusions, dosing interval, dosage, duration, and occasion of osteonecrosis, diagnosed by history and physical examination, were analyzed.
Results
The overall incidence of osteonecrosis was 0.94% (6/638). No significant relationship was observed between the incidence of osteonecrosis and demographic parameters, primary tumor, cumulative drug dose, or dosing interval. However, patients who developed osteonecrosis had a significantly greater mean number of infusions (p = .016) and significantly greater mean hours of infusion time (p = .0036).
Conclusions
The findings suggest positive correlation between the development of osteonecrosis and drug exposure as measured by number of infusions and total infusion hours. However, the relatively low incidence of osteonecrosis precluded definition of a direct dose–response relationship. © 2008 Wiley Periodicals, Inc. Head Neck, 2009</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>18853454</pmid><doi>10.1002/hed.20941</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1043-3074 |
| ispartof | Head & neck, 2009-02, Vol.31 (2), p.202-206 |
| issn | 1043-3074 1097-0347 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_902335794 |
| source | MEDLINE; Wiley Online Library All Journals |
| subjects | Adult Aged Aged, 80 and over Biological and medical sciences bisphosphonate Bone Density Conservation Agents - adverse effects Bones, joints and connective tissue. Antiinflammatory agents Cohort Studies Diphosphonates - adverse effects Diseases of the osteoarticular system Dose-Response Relationship, Drug Female Humans Incidence Infusions, Intravenous Male Mandible Maxilla Medical sciences Middle Aged osteonecrosis Osteonecrosis - chemically induced Osteonecrosis - epidemiology Otorhinolaryngology. Stomatology Pharmacology. Drug treatments Retrospective Studies Risk Factors Vascular bone diseases |
| title | Incidence and risk factors of bisphosphonate-associated osteonecrosis of the jaws |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T23%3A58%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Incidence%20and%20risk%20factors%20of%20bisphosphonate-associated%20osteonecrosis%20of%20the%20jaws&rft.jtitle=Head%20&%20neck&rft.au=Stumpe,%20Matthew%20R.&rft.date=2009-02&rft.volume=31&rft.issue=2&rft.spage=202&rft.epage=206&rft.pages=202-206&rft.issn=1043-3074&rft.eissn=1097-0347&rft_id=info:doi/10.1002/hed.20941&rft_dat=%3Cproquest_cross%3E902335794%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=902335794&rft_id=info:pmid/18853454&rfr_iscdi=true |